|
|
 |
|
Viewing report
|
|
|
|
Special Report: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis
Decision Resources, Inc., June 2009, Pages: 25
Although interviewed thought leaders acknowledge that available biological therapies have greatly improved treatment of juvenile idiopathic arthritis (JIA)—the most common rheumatic disease in children—they do not hesitate to point out unmet needs and remaining drug development opportunities in this field. When current treatments fail, severe disability and even death can result. The heterogeneous nature of JIA leaves room for drugs that target new targets while meeting the particular needs of the pediatric population.
This report features Decision Resources’ primary research:
- Epidemiology of juvenile idiopathic arthritis.
- Interviews with rheumatologists who treat juvenile idiopathic arthritis. See how the data we have collected and analyzed reveal the challenges and opportunities in this indication marketplace.
Questions Answered in This Report
- JIA is an umbrella term for seven distinct diagnoses. How are the various JIA subtypes defined? How are they diagnosed? How does their treatment differ?
- The drugs used in the treatment of JIA are identical to those used in adult rheumatic diseases. What are the first-line therapies for JIA? What factors drive prescribing decisions? How safe and efficacious are these treatments in children?
- Not all JIA patients are sufficiently treated with available therapies. Which specific unmet needs remain? What agents are in development for JIA? How will these agents fit into the treatment patterns for these diseases? What do thought leaders say about emerging agents?
Scope
- Overview of JIA: Oligoarthritis; polyarthritis; enthesitis-related arthritis; psoriatic arthritis; systemic JIA; diagnosis of JIA.
- Epidemiology: Ten-year forecast for United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
- Current therapies: nonsteroidal anti-inflammatory drugs (NSAIDs); corticosteroids; methotrexate; tumor necrosis factor-alpha (TNF-a) inhibitors; Orencia; Kineret; Rituxan.
- Emerging therapies: Rilonacept; canakinumab; tocilizumab.
- Opportunities in JIA: Qualitative market outlook for current and emerging agents; unmet needs.
- Primary research: Thought-leader interviews from the United States, France, Germany, and the United Kingdom.
Customers who bought this item also bought
Juvenile Idiopathic Arthritis - Disease-Subtype Heterogeneity Drives Diverse Treatment Options
Juvenile Idiopathic Arthritis (JIA): KOL Insights on Treatment Practices and Unmet Needs
Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Drug Delivery in Cancer - Technologies, Markets and Companies
Special Report: The Autoimmune Biologics Pipeline-A Competitive Review
Pharmaceutical Industry Dynamics 2010: Licensing Opportunities: Rheumatology
Rheumatoid Arthritis Drug Discoveries: what the future holds
Ankylosing Spondylitis: How Have Biological Therapies Affected the Market?
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
Pain Therapeutics - Drugs, Markets and Companies
|
|
|
|
